(Q44770176)

6 December 2017

Pharmacokinetics and safety of the ketolide telithromycin in patients with renal impairment (English)

1 reference

6 December 2017

1 reference

Jun Shi

1

1 reference

6 December 2017

Guy Montay

2

1 reference

6 December 2017

Sunny Chapel

3

1 reference

6 December 2017

Pierre Hardy

4

1 reference

6 December 2017

Jeffrey S Barrett

5

1 reference

6 December 2017

Marshall Sack

6

1 reference

6 December 2017

Thomas Marbury

7

1 reference

6 December 2017

Suzanne K Swan

8

1 reference

6 December 2017

Ramon Vargas

9

1 reference

6 December 2017

Violette Leclerc

10

1 reference

6 December 2017

Bruno Leroy

11

1 reference

6 December 2017

Vijay O Bhargava

12

1 reference

6 December 2017

1 March 2004

1 reference

The Journal of Clinical Pharmacology

6 December 2017

1 reference

6 December 2017

44

1 reference

6 December 2017

3

1 reference

6 December 2017

234-244

1 reference

Ketolides-telithromycin, an example of a new class of antibacterial agents

6 December 2017

1 reference

https://api.crossref.org/works/10.1177%2F0091270003262952

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003262952

Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003262952

Pharmacokinetics and absolute oral bioavailability of an 800-mg oral dose of telithromycin in healthy young and elderly volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003262952

Lack of effect of food on the bioavailability of a new ketolide antibacterial, telithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003262952

Telithromycin is as effective as amoxicillin/clavulanate in acute exacerbations of chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003262952

Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003262952

Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003262952

Efficacy of short-course therapy with the ketolide telithromycin compared with 10 days of penicillin V for the treatment of pharyngitis/tonsillitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003262952

Efficacy and tolerability of once-daily therapy with telithromycin for 5 or 10 days for the treatment of acute maxillary sinusitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003262952

Efficacy and safety of telithromycin in community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003262952

Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003262952

In vitro activities of the novel ketolide telithromycin (HMR 3647) against erythromycin-resistant Streptococcus species

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003262952

In vitro activity of telithromycin against Spanish Streptococcus pneumoniae isolates with characterized macrolide resistance mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003262952

Pharmacokinetics of the ketolide telithromycin after single and repeated doses in patients with hepatic impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003262952

The pharmacokinetics of clarithromycin and its 14-OH metabolite

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003262952

Clinical pharmacokinetics of clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003262952

Prediction of creatinine clearance from serum creatinine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003262952

Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003262952

Drug administration in patients with renal insufficiency. Minimising renal and extrarenal toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003262952

Effect of single and repeated oral doses of telithromycin on cardiac QT interval in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003262952

Effect of chronic renal failure on the disposition of highly hepatically metabolized drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003262952

Pharmacokinetics of sematilide in renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003262952

21 January 2018

Identifiers

DOI

10.1177/0091270003262952

1 reference

release_pym6csv6tzfudevmusfnygvfmy

6 December 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/pym6csv6tzfudevmusfnygvfmy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference